Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Nov 11, 2024 3:57pm
159 Views
Post# 36307172

Shorting analysis, risk

Shorting analysis, risk

Obviously, a few on here are shorting.
Looking at the upside. 

They have fast track approval for both MBc & pancreatic cancer.
A $5 million grant to add an additional arm, from PanCan & now administered by CGAR. These are global experts in pancreatic cancer. Giving not only guidance, but cash support for future endeavours.
They will be overseeing the implementation of the upcoming " registration enabling" trial.
That is the one, they announced possible accelerated approval. And they are being able to utilize existing previous  Trial results as the comparable. That reduces the cost, time & if determined, they can advance to licensing.

They clearly need financial support to progress with the panc trial. When that gets announced the price upside is multiples of existing.
and
will come with a trading hault.
meaning anyone shorting won't have time to cover
inlook forward to that day.
FYI, the upside could be much higher than you could ever imagine,
The present calc is roughly $12/billion.
That is more than 6x existing.
 

The downside?
it will never be zero. For argument sake use that number.
so give or take $1.
imho that risk ratio is insane.
You have been warned.

 

<< Previous
Bullboard Posts
Next >>